🇺🇸 177Lu-DOTATATE in United States
20 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 20
Most-reported reactions
- Abdominal Abscess — 2 reports (10%)
- Anaemia — 2 reports (10%)
- Blood Gastrin Increased — 2 reports (10%)
- Electrolyte Imbalance — 2 reports (10%)
- Hyperadrenocorticism — 2 reports (10%)
- Hypoalbuminaemia — 2 reports (10%)
- Leukopenia — 2 reports (10%)
- Malignant Neoplasm Progression — 2 reports (10%)
- Oedema — 2 reports (10%)
- Pulmonary Embolism — 2 reports (10%)
Other Oncology approved in United States
Frequently asked questions
Is 177Lu-DOTATATE approved in United States?
177Lu-DOTATATE does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for 177Lu-DOTATATE in United States?
Erasmus Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.